Fig. 5

SHP-1 agonist induces cell apoptosis through Lyn. A Whole-cell extracts of U2932 and OCI-Ly7 transfected with siRNAs against SHP-1 or control were assessed by Western blot analysis (left). The quantitative results of blotting were shown (right). B U2932 cells treated with SC-43 or ruxolitinib at indicated doses for 24 h were examined by Western blot analysis (left). The quantitative results of blotting were shown (right). C U2932 and OCI-Ly7 cells were transfected with Lyn-expressing or control plasmids for 48 h. The transfected cells were further treated with 10 μM SC-43 or DMSO for 24 h and examined by Western blot analysis (left). The quantitative results of blotting were shown (right). D In the present study, our data indicated that SHP-1 agonists (sorafenib analogues such as SC-43 and SC-60) enhanced SHP-1 activity and further reduced phosphorylation of Lyn and BTK. Dephosphorylation of Lyn and BTK inhibited cell survival signaling leading to cell apoptosis. In addition, SHP-1 agonists also dephosphorylated STAT3 as previously reported which might partly contribute to cell growth inhibition. Data are representative of three independent experiments. Student’s t-test, *P < 0.05; **P < 0.01; ***P < 0.001; ^#P < 0.05; ^##P < 0.01